Cargando…

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine. However, there are still some problems, including a relatively low response rate, innate mechanisms of resistance against immune checkpoint bloc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sagawa, Ray, Sakata, Seiji, Gong, Bo, Seto, Yosuke, Takemoto, Ai, Takagi, Satoshi, Ninomiya, Hironori, Yanagitani, Noriko, Nakao, Masayuki, Mun, Mingyon, Uchibori, Ken, Nishio, Makoto, Miyazaki, Yasunari, Shiraishi, Yuichi, Ogawa, Seishi, Kataoka, Keisuke, Fujita, Naoya, Takeuchi, Kengo, Katayama, Ryohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765052/ https://www.ncbi.nlm.nih.gov/pubmed/34874919 http://dx.doi.org/10.1172/jci.insight.153323

Ejemplares similares

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
por: Shimizu, Yuki, et al.
Publicado: (2022)

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
por: Ariyasu, Ryo, et al.
Publicado: (2021)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
por: Takahashi, Ken, et al.
Publicado: (2020)

Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma
por: Ninomiya, Hironori, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
por: Sakashita, Takuya, et al.
Publicado: (2022)

An extremely rare case of rapidly growing mediastinal well-differentiated liposarcoma with a sclerosing variant: a case report
por: Iwamoto, Naoya, et al.
Publicado: (2020)

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
por: Yanagitani, Noriko, et al.
Publicado: (2020)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
por: Gong, Bo, et al.
Publicado: (2019)

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020)

Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure
por: Sonoda, Dai, et al.
Publicado: (2020)

A rapidly growing mature mediastinal teratoma with a testicular epidermoid cyst and familial Mediterranean fever
por: Omura, Kenshiro, et al.
Publicado: (2019)

A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis)
por: Ukaji, Takao, et al.
Publicado: (2018)

Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma
por: Nakao, Masayuki, et al.
Publicado: (2022)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
por: Amino, Yoshiaki, et al.
Publicado: (2023)

Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection
por: Sonoda, Dai, et al.
Publicado: (2019)

Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma
por: Kondo, Yasuto, et al.
Publicado: (2022)

Novel knock‐in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin–targeting agents
por: Ukaji, Takao, et al.
Publicado: (2021)

Patient-specific simulation for tracheobronchial reconstruction procedures using 3-dimensional operable models: A proof-of-concept study
por: Hashimoto, Kohei, et al.
Publicado: (2022)

Thoracoscopic right upper lobectomy in a patient with bronchial and pulmonary vein anomalies
por: Mun, Mingyon, et al.
Publicado: (2020)

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Katayama, Ryohei, et al.
Publicado: (2019)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Uchibori, Ken, et al.
Publicado: (2017)

Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma
por: Saito, Yuichi, et al.
Publicado: (2016)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer
por: Nakao, Masayuki, et al.
Publicado: (2020)

DecoyFinder, a tool for finding decoy molecules
por: Adrià, Cereto Massagué, et al.
Publicado: (2012)

The “sensor domains” of plant NLR proteins: more than decoys?
por: Wu, Chih-Hang, et al.
Publicado: (2015)

Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis
por: Takagi, Satoshi, et al.
Publicado: (2021)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

The utility of three-dimensional computed tomography for prediction of tumor invasiveness in clinical stage IA lung adenocarcinoma
por: Kawaguchi, Yohei, et al.
Publicado: (2020)

Engineering ACE2 decoy receptors to combat viral escapability
por: Arimori, Takao, et al.
Publicado: (2022)

A 3-dimensional airway model for tracheobronchial surgery
por: Hashimoto, Kohei, et al.
Publicado: (2022)

Risk factors for bronchopleural fistula after lobectomy for lung cancer
por: Ichinose, Junji, et al.
Publicado: (2023)

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
por: Kitazono, Satoru, et al.
Publicado: (2019)

Plant polyadenylation factors: conservation and variety in the polyadenylation complex in plants
por: Hunt, Arthur G, et al.
Publicado: (2012)

Reconstitution of CPSF active in polyadenylation: recognition of the polyadenylation signal by WDR33
por: Schönemann, Lars, et al.
Publicado: (2014)

Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking
por: Mysinger, Michael M., et al.
Publicado: (2012)

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019)

Chemokine decoy receptors in inflammation
por: Graham, G
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_43dmsh6p3g5eqmeaks4j80ik9o